Innovating
Brain Resilience.
Caelium is a biopharmaceutical research and development company on a mission to make the brain stronger against degeneration caused by disease and injury. We develop therapeutic approaches designed to apply broadly across neurodegenerative conditions, including Alzheimer’s, Parkinson’s, Traumatic Brain Injury (TBI), and beyond.
"We focus on the structural integrity of the mind to prevent decline before it begins."
What Is Caelium
Caelium is a biopharmaceutical research and development company founded by internationally recognized leaders in brain imaging, radiology, and neurodegenerative disease research. The company was built on decades of work studying how brain degeneration unfolds across conditions such as Alzheimer’s and Traumatic Brain Injury.
Rather than approaching each disease in isolation, Caelium focuses on developing breakthrough therapies that address the shared degenerative processes underlying many neurological disorders. This research-driven foundation enables a more unified approach to fighting brain degeneration—transforming longstanding scientific insight into therapeutic treatments with the potential to impact a wide range of diseases and injuries.
The Team
Caelium is led by a distinguished collective of founders and researchers with deep expertise in neuroscience, advanced brain imaging, and translational medicine. Our team brings decades of experience from world-class clinical environments, dedicated to converting complex scientific discoveries into effective real-world therapies.
This commitment to clinical excellence and research integrity ensures that every breakthrough at Caelium is grounded in rigorous science and driven by the goal of restoring cognitive resilience for patients everywhere.
Donna Cross, PhD Co-Founder and CEO
Research Professor University of Utah
Department of Radiology and Imaging
Satoshi Minoshima, MD PhD, Co-Founder and Director
Professor and Anne G. Osborn
endowed Chair
University of Utah Department of Radiology and Imaging
Andrew Roberts, PhD Chief Science Officer
Associate Professor
University of Utah Department of Chemistry
Nicholas A. Frost, MD, PhD Clinical Advisor
Assistant Professor
University of Utah Department of Neurology
Annette Lavoie, PhD Commercialization Advisor
Startup business advisor for
University technology spinouts
Our Science
Caelium’s breakthrough is built around a single therapeutic treatment designed to address a shared biological process present across many brain diseases and injuries: neurodegeneration.
While these conditions differ in cause and presentation, they are linked by progressive loss of brain structure and function. By targeting this common neurodegenerative process, Caelium’s therapy can be applied across a wide range of indications rather than developed separately for each disease.
Lead
Alzheimer’s
Pipeline
ALS & MS
Pipeline
Parkinson’s
Trauma
TBI & SCI
UPDATES
Latest News
14, April 2026
Radiology Professor Develops Novel Approaches to Treating Alzheimer’s Disease | Radiology | U of U School of Medicine
14, April 2026
Efforts by local researcher close in on Alzheimer’s treatments – Park Record
14, April 2026
Utahn may be on verge of a significant breakthrough in treating Alzheimer’s – Deseret News